Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings

Jazz Pharmaceuticals (JAZZ) reported $897.84 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.5%. EPS of $1.68 for the same period compares to $2.68 a year ago.The reported revenue represents a surprise of -8.52% over the Zacks Consensus Estimate of $981.41 million. With the consensus EPS estimate being $4.51, the EPS surprise was -62.75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Royalties and contract revenues: $58.42 million versus $56.30 million estimated by 10 analysts on average. Revenues- Product sales, net: $839.42 million compared to the $925.39 million average estimate based on 10 analysts. The reported number represents a change of -0.3% year over year. Total revenues- Neuroscience- Oxybate- Xywav: $344.80 million versus the nine-analyst average estimate of $377.35 million. The reported number represents a year-over-year change of +9.4%. Total revenues- Neuroscience- Epidiolex/Epidyolex: $217.74 million versus $233.21 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change. Total revenues- Neuroscience- Sativex: $5.41 million versus the nine-analyst average estimate of $3.79 million. The reported number represents a year-over-year change of +97.7%. Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $382.05 million versus the nine-analyst average estimate of $415.54 million. The reported number represents a year-over-year change of +0.7%. Total revenues- Neuroscience- Total: $605.19 million versus the nine-analyst average estimate of $652.54 million. The reported number represents a year-over-year change of +4.2%. Total revenues- Oncology- Total: $229.45 million versus $269.04 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -10.9% change. Total revenues- Oncology- Rylaze: $94.23 million versus $104.20 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -8.3% change. Total revenues- Oncology- Defitelio/defibrotide: $40.66 million compared to the $47.89 million average estimate based on nine analysts. The reported number represents a change of -14.7% year over year. Total revenues- Oncology- Vyxeos: $29.54 million versus $34.56 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change. Total revenues- Oncology- Zepzelca: $63.03 million versus $80.75 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.1% change. View all Key Company Metrics for Jazz here>>>Shares of Jazz have returned +10.5% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks